Introduction
============

Osteosarcoma is the most common bone malignancy, usually arising from skeletal lesions.[@b1-ccrep-9-2016-031],[@b2-ccrep-9-2016-031] Extraosseous osteosarcoma is a rare, primary mesenchymal soft tissue tumor capable of producing osteoid, bone, or chondroid matrix,[@b1-ccrep-9-2016-031],[@b3-ccrep-9-2016-031],[@b4-ccrep-9-2016-031] accounting for approximately 4% of all osteosarcomas.[@b2-ccrep-9-2016-031],[@b4-ccrep-9-2016-031] A literature review yields very few cases of osteosarcoma primarily arising from the hepatic parenchyma.[@b5-ccrep-9-2016-031]--[@b15-ccrep-9-2016-031] The data on risk factors, epidemiology, pathogenesis, and treatment of this rare tumor are limited.[@b5-ccrep-9-2016-031]--[@b21-ccrep-9-2016-031] We report a case of primary hepatic osteosarcoma in a man in his 50s with a past medical history of hepatitis C and cirrhosis who expired 4 months after diagnosis. The Maimonides Medical Center IRB/Research Committee has stated that no IRB approval is needed for publication of this report.

Case Report
===========

A man in his 50s with a history of hepatitis C virus and liver cirrhosis presented with 5 days of progressive right upper quadrant pain. A computed tomography scan (CT scan) of the abdomen and pelvis showed a large liver mass ([Fig. 1](#f1-ccrep-9-2016-031){ref-type="fig"}). The patient was treated for possible liver abscess with antibiotics. The patient did not improve with antibiotics. A magnetic resonance imaging (MRI) was done due to persistence of symptoms, which demonstrated a 4.4 cm × 4.8 cm × 4.8 cm right hepatic lobe mass with a large area of necrosis with peripheral enhancement ([Fig. 2](#f2-ccrep-9-2016-031){ref-type="fig"}). Subsequently, a liver biopsy was performed that demonstrated a hepatic osteosarcoma. The core biopsy yielded fibroblastic malignant cells producing lace-like osteoid matrix ([Fig. 3](#f3-ccrep-9-2016-031){ref-type="fig"}). Rare osteoclast-like giant cells and mitotic figures were also seen ([Fig. 4](#f4-ccrep-9-2016-031){ref-type="fig"}). Liver parenchyma and carcinomatous element were absent. Extensive sampling of the liver did not show any evidence of carcinomatous or sarcomatous transformation, ruling out choriocarcinoma. Core biopsies of both benign and malignant liver tissues did not show any embryonic or fetal pattern differentiation, thereby excluding hepatoblastoma and hepatocellular carcinoma. On immunohistochemistry, the tumor cells were negative for HepPar1 and AE1/3 and reactive for vimentin. A whole-body positron emission tomography--computed tomography (PET/CT) scan also demonstrated malignant-level uptake in the 1.8 cm × 0.9 cm soft tissue nodule just anterior to the patellar surface of the left distal femur, later confirmed by MRI. Excisional biopsy of the deep left knee mass, which revealed pigmented villonodular synovitis (PVNS) and histological feature, did not resemble the tumor in the liver. The diagnosis of primary osteosarcoma was made for which the patient underwent portal vein embolization in preparation for a surgical resection of the right liver lobe. He was admitted six weeks after the embolization for dyspnea and abdominal distension and expired two weeks later.

Discussion
==========

Osteosarcomas usually arise from skeletal lesions and are charac terized by the production of osteoids by malignant cells.[@b1-ccrep-9-2016-031]--[@b4-ccrep-9-2016-031] Extraskeletal osteosarcoma (ESOS) accounts for less than 2% of all soft tissue sarcomas, and the most common anatomic sites are soft tissues of the limbs and the limb girdle.[@b1-ccrep-9-2016-031],[@b3-ccrep-9-2016-031],[@b4-ccrep-9-2016-031],[@b21-ccrep-9-2016-031] Primary osteosarcomas of parenchymal organs are very rare, but cases arising with the thyroid, kidney, gallbladder, breast, mesentery, uterus, brain, lung, bladder, heart, and colon have been reported.[@b22-ccrep-9-2016-031]--[@b32-ccrep-9-2016-031]

Primary osteosarcoma of the liver is an exceedingly rare hepatic tumor. A literature search yielded 11 case reports of primary hepatic osteosarcoma.[@b5-ccrep-9-2016-031]--[@b15-ccrep-9-2016-031] Four of the preceding patients had underlying liver cirrhosis.[@b5-ccrep-9-2016-031]--[@b8-ccrep-9-2016-031] Exclusion of an alternative liver neoplasm and osteosarcomatous foci in other parts of the body is the key to diagnose a primary osteosarcoma.[@b5-ccrep-9-2016-031]--[@b15-ccrep-9-2016-031] Thus, our patient underwent core biopsies of both benign and malignant liver parenchymas as well as an excisional biopsy of the left knee in order to rule out metastatic disease. The biopsy results were negative for other primary and metastatic liver tumors. The knee biopsy showed PVNS, which is a benign proliferative histiocytic disorder of the synovium. There are very few cases of patients with malignant pigmented villonodular synovitis (MPVNS) reported in the literature.[@b33-ccrep-9-2016-031],[@b34-ccrep-9-2016-031] Our patient's knee biopsy did not show any cancerous cell, which resembled MPVNS or tumor in the liver.

The pathogenesis of primary liver osteosarcoma is unclear. In general, several etiological factors have been implicated in the pathogenesis of cancer, which include age, lifestyle, radiation, chemotherapy, ischemic stress, trauma, genetic predisposition, and infections such as hepatitis. Previous exposure to radiation has been described as a risk factor for the develop ment of ESOS.[@b4-ccrep-9-2016-031],[@b20-ccrep-9-2016-031] Our patient did not have a history of exposure to radiation. Sumiyoshi and Niho suggested the possible tumorigenesis of the proliferating mesenchymal tissues in the cirrhotic liver.[@b6-ccrep-9-2016-031] Since our patient is the fifth case report of primary hepatic osteosarcoma who had underlying liver cirrhosis, it is of great interest to study the further role of cirrhosis in the pathogenesis of this rare tumor.

ESOS tends to occur in late adulthood, and most patients are in the fifth to seventh decades at the time of diagnosis compared with the osteosarcoma of bone, which occurs in the younger age group.[@b1-ccrep-9-2016-031]--[@b4-ccrep-9-2016-031] It has poor prognosis. Lee et al reported that five-year survival of ESOS was 37% in a review of 40 patients, whereas it was 16% in a brief review of ESOS between 1975 and 2009 in Norway as reported by Kjetil Berner et al.[@b3-ccrep-9-2016-031],[@b20-ccrep-9-2016-031] The majority of primary hepatic osteosarcoma patients were older than 50 years and died shortly after diagnosis, despite surgical resection.[@b5-ccrep-9-2016-031]--[@b14-ccrep-9-2016-031] There was a single report of a 19-year-old patient who was tumor free for 3 years after surgical resection and adjuvant chemotherapy.[@b15-ccrep-9-2016-031]

Conclusion
==========

Because extraosseous osteosarcoma is so rare, has no proven therapy, and has a dire prognosis, it should be conside red a separate entity from osseous osteosarcoma, despite similar histopathology. To date, it appears that surgical resection with adjuvant chemoradiation is the best treatment choice,[@b16-ccrep-9-2016-031]--[@b21-ccrep-9-2016-031] although due to the rarity of the disease, no evidence-based treatment protocols exist.
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![CT showing 4.8 cm × 4.2 cm × 5.9 cm peripheral low-attenuation lesion with small peripheral septations within the right hepatic lobe.](ccrep-9-2016-031f1){#f1-ccrep-9-2016-031}

![MRI demonstrating a mildly heterogeneous T2 hyperintense lesion in the right hepatic lobe, measuring approximately 4.4 cm × 4.8 cm × 4.9 cm.](ccrep-9-2016-031f2){#f2-ccrep-9-2016-031}

![Neoplastic cells with osteoid deposition (hematoxylin and eosin \[H&E\] × 100).](ccrep-9-2016-031f3){#f3-ccrep-9-2016-031}
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